TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23326650

Group type: EXPERIMENTAL
Intervention: Weight loss (WL) intervention including meal replacements and structured exercise training
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Weight loss (WL) intervention
Number of subjects: 51

Group type: COMPARATOR
Intervention: Weight stable (WS) group
Number of subjects: 51
Study: 20697941

Group type: EXPERIMENTAL
Intervention: Topical application of Xiaozheng Zhitong Paste (XZP) in addition to basic therapy (3L analgesia)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Basic therapy (3L analgesia) without XZP
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Topical application of XZP
Number of subjects: 124
Study: 18260482

Group type: EXPERIMENTAL
Intervention: Above-elbow plaster cast for 3 weeks followed by below-elbow plaster cast for 3 weeks
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Below-elbow plaster cast for 6 weeks
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Immediate mobilisation
Number of subjects: 102
Study: 15787815

Group type: EXPERIMENTAL
Intervention: Spironolactone 200 mg daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 50 mg daily or 100 mg for 10 days per month if premenopausal
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oral antiandrogens (combined results of spironolactone and cyproterone acetate)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oral antiandrogens
Number of subjects: 80
Study: 11994342

Group type: EXPERIMENTAL
Intervention: Insulin tolerance test (ITT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ARG plus GHRH test
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ARG plus L-DOPA test
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ARG test
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: L-DOPA test
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Serum IGF-I levels
Number of subjects: 39
Study: 9649640

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 15 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 30
Study: 7716041

Group type: EXPERIMENTAL
Intervention: Multidisciplinary bedside notes
Number of subjects: 0
Study: 2653414

Group type: EXPERIMENTAL
Intervention: Progestational agents
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study: 31317576

Group type: EXPERIMENTAL
Intervention: Vaccination of healthcare workers
Number of subjects: 0
Study: 29188876

Group type: EXPERIMENTAL
Intervention: Erythrocyte membrane monounsaturated fatty acids (MUFAs) and saturated fatty acids (SFAs)
Number of subjects: 61
Study: 24811578

Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine every day for 1 month
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 20 mg tadalafil on demand 2 hours before intercourse
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: paroxetine and tadalafil on demand 2 hours before intercourse
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study: 24100785

Group type: EXPERIMENTAL
Intervention: Zotepine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 39
Study: 21665058

Group type: EXPERIMENTAL
Intervention: FLU-FOBT group
Number of subjects: 1372

Group type: COMPARATOR
Intervention: FLU-only group
Number of subjects: 1372
Study: 19390107

Group type: EXPERIMENTAL
Intervention: Computerized clinical decision support system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control units (alerts hidden but tracked)
Number of subjects: 0
Study: 16542296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 15290412

Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg and 3 mg
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study: 11742045

Group type: EXPERIMENTAL
Intervention: Supportive‐expressive group therapy
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 235
Study: 9479604

Group type: EXPERIMENTAL
Intervention: Preoperative Duplex Scan (DS)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Postoperative Duplex Scan (DS)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ligation of gastrocnemius veins (GV)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No ligation of gastrocnemius veins (GV)
Number of subjects: 180
Study: 8493295

Group type: EXPERIMENTAL
Intervention: Electroencephalographic (EEG) sleep assessments after successful treatment
Number of subjects: 29
Study: 2442826

Group type: EXPERIMENTAL
Intervention: dicumarol (n = 42)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Control group (n = 46)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: dicumarol in stages III and IV (n = 45)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Control group in stages III and IV
Number of subjects: 463
Study: 31959030

Group type: EXPERIMENTAL
Intervention: Incentives plus counseling intervention
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Incentives-only intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study: 28468616

Group type: COMPARATOR
Intervention: Real stimulation group
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 55
Study: 26492477

Group type: EXPERIMENTAL
Intervention: 5 mg midodrine hydrochloride
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 24200030

Group type: EXPERIMENTAL
Intervention: SF-12 (generic HRQoL)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: EDQOL (disease-specific HRQoL)
Number of subjects: 63
Study: 21436319

Group type: EXPERIMENTAL
Intervention: Corticosteroids + antifungal
Number of subjects: 92

Group type: COMPARATOR
Intervention: Corticosteroids only
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Antifungal only
Number of subjects: 92
Study: 18297267

Group type: EXPERIMENTAL
Intervention: Intermittent bolus injections (IB) of meropenem 1 g every 12 h
Number of subjects: 6

Group type: COMPARATOR
Intervention: Continuous infusion (CI) of meropenem 0.5 g loading dose followed by 2 g over 24 h
Number of subjects: 6
Study: 16611387

Group type: EXPERIMENTAL
Intervention: Polish meat diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Danish meat diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vegetarian diet
Number of subjects: 12
Study: 14623657

Group type: EXPERIMENTAL
Intervention: Active glyceryl trinitrate transdermal patch
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 86
Study: 10809855

Group type: EXPERIMENTAL
Intervention: Good wound care for 24 weeks
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Good wound care for 4 weeks
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Rate of healing (area healed per week)
Number of subjects: 104
Study: 8705095

Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release (group 1)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional open carpal tunnel release (group 2)
Number of subjects: 126
Study: 1642936

Group type: EXPERIMENTAL
Intervention: ketorolac trometamol 10 mg administered 4‐hourly by intermittent i.m. injection or by continuous i.m. infusion
Number of subjects: 67

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: ketorolac trometamol
Number of subjects: 67
Study: 6829920

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (0.5% bupivacaine with epinephrine intraoperatively; 0.25% bupivacaine with epinephrine every 3 hours postoperatively)
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia (controlled ventilation with N2O‐O2, intravenous fentanyl and pancuronium bromide; narcotic analgesics intramuscularly on demand postoperatively)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 60
Study: 29676480

Group type: EXPERIMENTAL
Intervention: Medication compliance and insight into schizophrenia
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Expert witness explanation regarding medication compliance and insight
Number of subjects: 173
Study: 27724965

Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (7-10 mmHg)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Standard-pressure pneumoperitoneum (12-16 mmHg)
Number of subjects: 280
Study: 24720702

Group type: EXPERIMENTAL
Intervention: Ledipasvir and sofosbuvir for 8 weeks
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Ledipasvir and sofosbuvir plus ribavirin for 8 weeks
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Ledipasvir and sofosbuvir for 12 weeks
Number of subjects: 647
Study: 23771784

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin algorithm
Number of subjects: 130
Study: 19201496

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg daily)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 18036719

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5mg daily
Number of subjects: 8224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8224
Study: 16650232

Group type: EXPERIMENTAL
Intervention: Albendazole single dose (400 mg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg for 3 days)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 1% permethrin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 1% permethrin + albendazole single dose (400 mg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 1% permethrin + albendazole (400 mg for 3 days)
Number of subjects: 150
Study: 12880714

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 21

Group type: COMPARATOR
Intervention: Males
Number of subjects: 21
Study: 10961748

Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate (NaP) solution
Number of subjects: 300

Group type: COMPARATOR
Intervention: Polyethylene glycol lavage
Number of subjects: 300

Group type: COMPARATOR
Intervention: Senna compound
Number of subjects: 300
Study: 9124864

Group type: EXPERIMENTAL
Intervention: 400 mg of pefloxacin twice daily for 5 days (group A)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 400 mg of pefloxacin twice daily for 7 days (group B)
Number of subjects: 46
Study: 1304992

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 40
Study: 4025304

Group type: EXPERIMENTAL
Intervention: Food frequency questionnaire
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 24-hour recall
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Three-day food record
Number of subjects: 82

Group type: COMPARATOR
Intervention: Food frequency questionnaire and three-day food record
Number of subjects: 82
Study: 31718738

Group type: EXPERIMENTAL
Intervention: After Deployment, Adaptive Parenting Tools program (ADAPT), a 14-session group-based parenting intervention
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: After Deployment, Adaptive Parenting Tools program (ADAPT)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 181
Study: 29237339

Group type: EXPERIMENTAL
Intervention: Rhythm-and-music-based therapy (R-MT), n=37
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Horse-riding therapy (H-RT), n=37
Number of subjects: 106

Group type: COMPARATOR
Intervention: Delayed intervention (control group), n=32
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Rhythm-and-music-based therapy (R-MT) and Horse-riding therapy (H-RT)
Number of subjects: 106
Study: 26972606

Group type: EXPERIMENTAL
Intervention: arginine+exercise (A‐E)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: exercise+placebo (EXE)
Number of subjects: 16

Group type: COMPARATOR
Intervention: arginine (ARG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: control (CON)
Number of subjects: 16
Study: 24693891

Group type: EXPERIMENTAL
Intervention: Hyperimmune globulin
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 22784835

Group type: EXPERIMENTAL
Intervention: 52 mg hydrated implant
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 84 mg hydrated implant
Number of subjects: 45

Group type: COMPARATOR
Intervention: 84 mg nonhydrated implant
Number of subjects: 45
Study: 21167080

Group type: EXPERIMENTAL
Intervention: Routine treatment with sarpogrelate (300 mg/day)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Routine treatment without sarpogrelate
Number of subjects: 268
Study: 17435520

Group type: EXPERIMENTAL
Intervention: Corneal Refractive Therapy (CRTH) lens (Dk = 100)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 20
Study: 15616299

Group type: COMPARATOR
Intervention: Tigecycline single-dose (12.5 to 300 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tigecycline multiple-dose (25 to 100 mg every 12 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tigecycline variable volume and infusion rate (100 mg loading dose, followed by 50 mg every 12 h for 5 days)
Number of subjects: 0
Study: 11122886

Group type: EXPERIMENTAL
Intervention: High-dose pulse therapy with 13-cis-retinoic acid (13-cis-RA) after intensive chemoradiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4-HPR (fenretinide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ATRA (all-trans-retinoic acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 13-cis-retinoic acid (13-cis-RA)
Number of subjects: 0
Study: 9056730

Group type: EXPERIMENTAL
Intervention: Dowdo (wheat-milk gruel)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Khitchri (rice-lentil mixture)
Number of subjects: 76
Study: 8364131

Group type: EXPERIMENTAL
Intervention: Ranitidine (n = 46)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo (n = 46)
Number of subjects: 92
Study: 3794070

Group type: EXPERIMENTAL
Intervention: Pure tones (220, 1100, or 3850 Hz)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Complex tone (18-tone complex with components between 110 and 7260 Hz)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pure tones (experiment 2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Complex tone (experiment 2)
Number of subjects: 12
Study: 30919883

Group type: EXPERIMENTAL
Intervention: Tdap vaccination
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: BCG given with Tdap or after Tdap
Number of subjects: 75
Study: 29657199

Group type: EXPERIMENTAL
Intervention: Non-obese group (BMI <23 Kg/m2)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Overweight/obese group (BMI >23 Kg/m2)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 51
Study: 26833209

Group type: EXPERIMENTAL
Intervention: Protocol-based care management delivered by medical assistants
Number of subjects: 2076
Study: 22999393

Group type: EXPERIMENTAL
Intervention: KT (blood flow restriction with occlusion pressure of approximately 230mmHg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HT (normobaric hypoxic exposure with blood oxyhaemoglobin levels of approximately 80%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: CT (no additional stimulus)
Number of subjects: 30
Study: 21091926

Group type: EXPERIMENTAL
Intervention: Estimates of gestational age using women's report of last menstrual period and physical examination
Number of subjects: 4484

Group type: COMPARATOR
Intervention: Ultrasound for determining eligibility
Number of subjects: 4484
Study: 18431947

Group type: EXPERIMENTAL
Intervention: Physical activity level; perceived benefits of physical activity; self-efficacy for leisure time physical activity; perceived school climate for girls' physical activity influenced by teachers
Number of subjects: 1511

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 1511

Group type: EXPERIMENTAL
Intervention: Race/Ethnicity (Blacks vs. Whites)
Number of subjects: 1511

Group type: EXPERIMENTAL
Intervention: Self-efficacy; perceived benefits; race/ethnicity; teachers' support for girls' physical activity
Number of subjects: 1511

Group type: EXPERIMENTAL
Intervention: Overall model
Number of subjects: 1511
Study: 17173588

Group type: EXPERIMENTAL
Intervention: Erbium:YAG laser plus topical 5-flurouracil
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (not specified what treatment)
Number of subjects: 9
Study: 12686924

Group type: EXPERIMENTAL
Intervention: Marginal flap
Number of subjects: 27

Group type: COMPARATOR
Intervention: Paramarginal flap
Number of subjects: 27
Study: 11168236

Group type: EXPERIMENTAL
Intervention: IMZ implants
Number of subjects: 61

Group type: COMPARATOR
Intervention: Brånemark implants
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both IMZ and Brånemark implants
Number of subjects: 61
Study: 9114824

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Copolymer 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosteroids and corticotropin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protein growth factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4‐aminopyridine and 3,4‐diaminopyridine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental agents (other interferons, methotrexate, linomide, monoclonal antibodies, T‐cell receptor peptides, 2‐chlorodeoxyadenosine)
Number of subjects: 0
Study: 8315363

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological interventions
Number of subjects: 0
Study: 3812669

Group type: EXPERIMENTAL
Intervention: Resting with a 750-kcal mixed meal (14% protein, 31% fat, 55% carbohydrate)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Resting with no meal
Number of subjects: 16

Group type: COMPARATOR
Intervention: 30 min of cycling with no meal
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 30 min of cycling, meal 30 min before exercise
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 30 min of cycling, meal immediately after exercise
Number of subjects: 16
Study: 29223182

Group type: EXPERIMENTAL
Intervention: Reading life stories (n = 19)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Reading file notes (n = 21)
Number of subjects: 40
Study: 26589483

Group type: EXPERIMENTAL
Intervention: Copenhagen Adduction exercise (CA) - 8-week supervised progressive training program
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group - continued training as usual
Number of subjects: 24
Study: 23452940

Group type: EXPERIMENTAL
Intervention: Telephone-supported comprehensive lifestyle intervention programme (CLIP: written structured diet and exercise advice, plus seven telephone sessions with the Heart Foundation Health Information Service)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual care from their general practitioner (control: written general lifestyle advice)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CLIP
Number of subjects: 49
Study: 22858215

Group type: EXPERIMENTAL
Intervention: Psychoeducation program alone
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Psychoeducation program plus online peer support
Number of subjects: 407

Group type: COMPARATOR
Intervention: Attentional control condition
Number of subjects: 407
Study: 20493480

Group type: EXPERIMENTAL
Intervention: Endoscopic dilation with an achalasia balloon
Number of subjects: 39

Group type: COMPARATOR
Intervention: Surgical removal of the ring
Number of subjects: 39
Study: 18221251

Group type: EXPERIMENTAL
Intervention: Fructose (40 g, 12% solution)
Number of subjects: 50

Group type: COMPARATOR
Intervention: High fructose corn syrup (HFCS)
Number of subjects: 50
Study: 20877359

Group type: EXPERIMENTAL
Intervention: Chemotherapy with CA 19-9 monitoring
Number of subjects: 0
Study: 16215338

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 12140392

Group type: EXPERIMENTAL
Intervention: Losartan potassium (50 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 12
Study: 9935257

Group type: EXPERIMENTAL
Intervention: Alatrofloxacin (200 mg intravenous)
Number of subjects: 492

Group type: COMPARATOR
Intervention: Cefotetan (2 g intravenous)
Number of subjects: 492
Study: 8148278

Group type: EXPERIMENTAL
Intervention: Doxycycline 0.1 g twice daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lymecycline 0.6 g twice daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3130927

Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate 500 mg weekly with proguanil hydrochloride 200 mg daily
Number of subjects: 767

Group type: COMPARATOR
Intervention: Chloroquine 500 mg weekly with sulfadoxine 500 mg‐pyrimethamine 25 mg weekly
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate with proguanil hydrochloride
Number of subjects: 767

Group type: COMPARATOR
Intervention: Chloroquine with sulfadoxine‐pyrimethamine
Number of subjects: 767
Study: 27121082

Group type: EXPERIMENTAL
Intervention: Nonverbal measure of hunger (squeezing a dynamometer)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Verbal measure of hunger (traditional self-report rating scale)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Nonverbal measure of hunger followed by verbal measure
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Only nonverbal measure of hunger
Number of subjects: 106
Study: 27737714

Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy (MBCT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 60
Study: 24633823

Group type: EXPERIMENTAL
Intervention: Prasugrel plus bivalirudin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel plus unfractionated heparin
Number of subjects: 0
Study: 22494826

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) supplementation (100,000 IU every 3 months for 18 months)
Number of subjects: 3046

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3046
Study: 20975054

Group type: EXPERIMENTAL
Intervention: Extended-release melatonin (Circadin®) at a dose of 2 mg 1 hour before bedtime for 8 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48